Clinical Significance of Marginal Acute Inflammation for Stage II Colon Cancer
Sponsor
Sun Yat-sen University (Other)
Overall Status
Completed
CT.gov ID
NCT06135558
Collaborator
(none)
1,167
93
Study Details
Study Description
Brief Summary
Marginal acute inflammation would make reporting the serosal involvement of tumors controversial. We aimed to investigate the clinical significance and explore the prognostic value of MAI for stage II localized colon cancer.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Study Design
Study Type:
Observational
Actual Enrollment
:
1167 participants
Observational Model:
Cohort
Time Perspective:
Retrospective
Official Title:
Presence and Clinical Significance of Marginal Acute Inflammation for Stage II Colon Cancer
Actual Study Start Date
:
Jan 30, 2016
Actual Primary Completion Date
:
Dec 30, 2022
Actual Study Completion Date
:
Oct 30, 2023
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| T3 patient staged T3 without marginal acute inflammation |
Diagnostic Test: MAI detection
to detect the presence of marginal acute inflammation
|
| MAI patient with marginal acute inflammation |
Diagnostic Test: MAI detection
to detect the presence of marginal acute inflammation
|
| T4 patient staged T4 without marginal acute inflammation |
Diagnostic Test: MAI detection
to detect the presence of marginal acute inflammation
|
Outcome Measures
Primary Outcome Measures
- DFS [5 year]
disease free survival
Eligibility Criteria
Criteria
Ages Eligible for Study:
18 Years
to 65 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
- (1) colon cancer patients with the preoperative staging of stage I-III who lacked distant metastasis; (2) patients who underwent radical resection, with postoperative pathology confirmed as pT3-4N0M0; and (3) complete follow-up information
Exclusion Criteria:
- (1) patients who received neo-adjuvant therapy; (2) patients with multiple primary colorectal cancer; and (3) patients with a history of malignant tumors
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Sun Yat-sen University
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
Yanhong Deng,
M.D.,
Sun Yat-sen University
ClinicalTrials.gov Identifier:
NCT06135558
Other Study ID Numbers:
- GIH-SYip32
First Posted:
Nov 18, 2023
Last Update Posted:
Nov 18, 2023
Last Verified:
Nov 1, 2023
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms: